Researchers reveal protospacer adjacent motif mutations (PAM sites) on the NRF2 gene of cancers could be used to guide CRISPR gene editing.
List view / Grid view
Filter the results
Researchers develop a knock-in mouse expressing human angiotensin-converting enzyme 2 (hACE2) to model SARS-CoV-2 infection for research and therapeutic or vaccine testing.
CRISPR screening utilises the power and precision of CRISPR-Cas9 gene editing to reveal and validate novel drug targets or to study the underlying causes of disease.
Researchers use CRISPR-Cas9 gene-editing to establish gangliosides are invoved in hepatitis A entering liver cells, revealing a potential drug target.
Induced pluripotent stem cells made to produce insulin and CRISPR, used to correct a genetic defect, cured Wolfram syndrome in mice.
Researchers have used CRISPR-Cas9 to screen the genome for possible targets that could be used in potential treatments for muscular dystrophy.
A study has shown that plasmids use type IV CRISPR-Cas against competing plasmids, leading the researchers to suggest the method as a novel way to tackle multi-drug resistant bacteria.
A new Cas13 RNA screen has been used to establish guide RNAs for the COVID-19 coronavirus and human RNA segments which could be used in vaccines, therapeutics and diagnostics.
Using a combination of Cas9 and Cas12a, Canadian researchers have enabled CRISPR methods to edit multiple genes at the same time.
A new systematic investigation on the role of solute carriers could lead to further insights into how the transporters affect the uptake and activity of drugs.
Researchers have shown that CRISPR-Cas3 can successfully attack C. difficile in vitro and in mice, by causing DNA damage to the pathogen.
A study has shown that altering amino acid residues in Cas9 to produce new variants can produce a vector with increased gene editing specificity.
A new study has revealed how bacterial immune systems can be harmful for their hosts and why they are not found in all bacteria.
Arguments filed in opposition to a patent for foundation CRISPR-Cas9 intellectual property have been broadly rejected by the European Patents Office.
Researchers have developed a new CRISPR technique, using a minigene, which was inserted into mouse DNA, resulting in improved liver disease symptoms.